Megan McHenry

About Megan McHenry

Megan S. McHenry, MD, MS, FAAP is a pediatrician and an Assistant Professor of Pediatrics in the Ryan White Center for Pediatric Infectious Disease and Global Health at Indiana University School of Medicine. Dr. McHenry's research focuses on early childhood development in children living in resource-limited settings. This work is frequently aligned with community-engaged research and dissemination and implementation science frameworks. She primarily conducts research in collaboration with the Academic Model for Providing Access to Healthcare (AMPATH) Research Network in Kenya. Dr. McHenry currently has a career development award through the National Institutes of Health to develop a neurodevelopmental screening program for children born to HIV-infected mothers in Kenya.

Dr. McHenry is also the Director of Pediatric Global Health Education and a co-Director of the Morris Green Physician-Scientist Development Program at Indiana University School of Medicine. In additional to global health lectures, she also educates residents and students on early childhood development, basic biostatistical techniques, research methodologies, and research ethics. She mentors multiple pediatric fellows, residents, and medical students interested in early childhood development within global contexts.

Review: Comparison of chest CT findings between COVID-19 pneumonia and other types of viral pneumonia: A two-center retrospective study

A retrospective review comparing the pulmonary chest CT findings of patients with COVID-19 pneumonia with those with other types of viral pneumonia found that a peripheral distribution, a lesion range > 10 cm, involvement of 5 lobes, presence of hilar and mediastinal lymphRead More
Feature image not available

Review: Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19

In this study, 10 independent clinical predictors were identified and used to develop a risk score (COVID-GRAM) that predicts development of critical illness from COVID-19.  Study took place in China: A retrospective cohort of patients with COVID-19 was established asRead More
Feature image not available

Review: SARS-CoV-2 (COVID-19): What do we know about children? A systematic review

A systematic review on pediatric COVID-19 finds that children appear to be less affected by infection with SARS-CoV-2 compared to adults.  24 studies were found that focused on literature related to SARS-CoV- in pediatric populations, 16 of which were pre-printsRead More
Feature image not available

Review: Detection of SARS-CoV-2 in placental and fetal membrane samples

This is a brief case series study on the placental/membrane SARS-CoV2 RNA PCR swab results of 11 symptomatic mothers with confirmed COVID-19 infection in pregnancy; only 3 were positive for SARS-CoV-2. All charts pregnant women diagnosed with COVID-19 who gaveRead More
Feature image not available

Review: Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state

Among 1438 patients hospitalized with COVID-19 in metropolitan New York in this publication, treatment with hydroxychloroquine, azithromycin, or both was not associated with significantly lower in-hospital mortality. A retrospective study aimed to describe the association between use of hydroxychloroquine, withRead More
Feature image not available

Review: Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial

  This was an open-label, randomized trial comparing clinical outcomes of those on triple combination therapy to those on lopinavir-ritonavir alone, which found that early triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shorteningRead More
Feature image not available

Review: Prolonged persistence of SARS-CoV-2 RNA in body fluids

Using an accelerated failure time-based modeling study, estimated median time virus RNA detection ranged from 15.6-24.5 days in mild COVID-19 cases to 30.9-33.9 days in severe cases.  This was a prospective analysis of 49 coronavirus disease cases in Guangdong, ChinaRead More
Feature image not available

Get Involved with Indiana CTSI